Press Releases

Aspen Neuroscience to Present at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Presentation Covers Aspen’s Autologous iPSC-derived Approach for Neuron Replacement Therapy in Trial for Parkinson’s Disease SAN DIEGO, May 14, 2025 /PRNewswire/ — Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D., will present at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held this week May 13-17, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The annual

Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

SAN DIEGO and NEW YORK, May 7, 2025 /PRNewswire/ — Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) therapy being studied in patients with moderate to advanced Parkinson’s Disease (PD). After recent publication in Parkinsonism and Related Disorders, detailed 6-month data on

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting

Presentations Cover Automated Manufacturing of Aspen’s Autologous iPSC-derived Neuron Replacement Therapy for Parkinson’s Disease SAN DIEGO and NEW ORLEANS, May 7, 2025 /PRNewswire/ — Aspen Neuroscience scientists, led by Chief Scientific Officer Xiaokui Zhang, Ph.D., will present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting, held this week May 7-10 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer

CFO Further Positions Company for Growth and Continued Advancement of Clinical Programs SAN DIEGO, April 30, 2025 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing personalized, autologous cell therapies, has appointed Dalen Meeter, CPA, MBA, as Chief Financial Officer (CFO). “We are excited to welcome Dalen to our executive team during this significant period of growth

Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

Clinical Trial Assesses Safety and Tolerability of Escalating Doses of ANPD001 Autologous, Dopaminergic Neuronal Cell Replacement Therapy SAN DIEGO, Jan. 13, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. has successfully completed dose escalation and the first two cohorts of patients in the ASPIRO study, an ANPD001 Phase 1/2a clinical trial in Parkinson’s Disease (PD). The Autologous-derived Study of a

Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson’s Disease

Company is scaling out production of ANPD001 investigational cell therapy SAN DIEGO, Jan. 8, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. has advanced its plans for automating production of ANPD001, including a capacity expansion for autologous manufacturing at its San Diego-based GMP facility. ANPD001, an investigational cell therapy program for treating people with Parkinson’s disease (PD), is currently being studied

Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at UBS Global Healthcare Conference

SAN DIEGO, Nov. 12, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer Kameel Farag will present company updates in a fireside chat today at 4:15 pm PT at the UBS Global Healthcare Conference in Rancho Palos Verdes, Calif., where he will detail Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. The UBS Global Conference is designed to

Aspen Neuroscience Announces Collaboration and License Agreement with Cell X Technologies

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — Aspen Neuroscience has entered into a collaboration and license agreement with Cell X Technologies to advance Aspen’s plans for automating the iPSC stage of its autologous manufacturing platform. Aspen will leverage its established bioinformatics-based platform, and will lead all discovery, preclinical, development and commercialization activities associated with the advancement of automated manufacturing for

Endpoints News Honors Aspen Neuroscience Co-Founder Dr. Jeanne Loring in “20 Women Breaking New Ground”

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — EndPoints News has named Jeanne Loring, PhD, Aspen Neuroscience co-founder and senior advisor, a recipient of the 20 Women Breaking New Ground in BioPharma. The publication’s annual 2024 Women in BioPharma R&D Special Report recognizes the field’s most inspiring and driven women leaders. “Dr. Jeanne Loring is one of the earliest pioneers in human stem cell

Aspen Neuroscience to Showcase Advances in Autologous Cell Therapy Development at 2024 Cell & Gene Meeting on the Mesa

SAN DIEGO and PHOENIX, Oct. 7, 2024 /PRNewswire/ — Presentations by Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D. and Chief Technology Officer Kim Raineri will highlight the latest therapeutic and corporate developments, at the annual Cell & Gene Meeting on the Mesa, held this week in Phoenix, Ariz. and live-streamed globally. Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa

Aspen Neuroscience Announces Expansion of Autologous Cell Therapy Manufacturing in San Diego

Company Outlines Plans for Industrialization of Personalized Cell Therapy Manufacturing SAN DIEGO, Oct. 1, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing personalized (autologous) cell therapies, announced the expansion of its San Diego footprint near its headquarters in Torrey Pines, with a new 22,000 square foot facility for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell

Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer, Kameel Farag, will present this week at three biotechnology investor conferences, where he will provide company updates detailing Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. About Aspen Neuroscience Aspen Neuroscience, Inc., headquartered in San Diego, is dedicated to autologous regenerative medicine. The company’s

Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data from this cohort has been accepted for late breaking presentations this week at the MDS International Congress of Parkinson’s Disease and Movement Disorders, taking place in Philadelphia September 27

Study of ANPD001 Autologous Neuronal Cell Replacement Treatment Approach Published in Journal of Neurosurgery

SAN DIEGO, July 29, 2024 /PRNewswire/ — The Journal of Neurosurgery has published online a study by the Wisconsin National Primate Research Center at the University of Wisconsin, Madison regarding a novel cell transplantation approach being used for delivery of ANPD001, an autologous, dopaminergic neuronal cell replacement under investigation by Aspen Neuroscience as a potential treatment for Parkinson’s Disease. The study by the Wisconsin

Aspen Neuroscience to Present at 2024 Raymond James Biotech Private Company Showcase July 18

SAN DIEGO, July 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a clinical-stage private biotechnology company developing personalized regenerative therapies, announced today that president and CEO Damien McDevitt, PhD, will participate in a virtual fireside chat at the 2024 Raymond James Biotech Private Company Showcase on Thursday, July 18 at 11 a.m. PT / 2 p.m. ET. About Aspen NeuroscienceAspen Neuroscience, Inc., headquartered in San Diego, is

Aspen Neuroscience to Present at Stifel 2024 Cell Therapy Forum July 9

SAN DIEGO, July 8, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. a clinical-stage private biotechnology company developing personalized regenerative therapies, announced today that president and CEO Damien McDevitt, PhD, will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum this Tuesday, July 9 at 10:35am PT (1:35pm ET). A live webcast of the fireside chat will be broadcast

Parkinson’s Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients’ Own Autologous Replacement Neurons

Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System SAN DIEGO, June 20, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced today that it is utilizing the MRI-guided ClearPoint® Navigation System for all patients enrolled in the recently launched ASPIRO Phase 1/2a clinical trial for transplantation of dopaminergic neuron precursor cells (DANPCs) in patients

Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting

Presentations Cover Aspen’s Autologous iPSC-derived Approach for Neuron Replacement Therapy in Trial for Parkinson’s Disease SAN DIEGO and VANCOUVER, BC, May 30, 2024 /PRNewswire/ — Aspen Neuroscience will present this week to a global audience of clinicians, regulators, researchers, technologists and industry partners at the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, May

Aspen Neuroscience Receives CLIN2 Grant for ANPD001 from California Institute for Regenerative Medicine (CIRM)

Award Will Support the First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy SAN DIEGO, May 15, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a California-based private biotechnology company developing personalized regenerative therapies, has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, to support

Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease

First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy SAN DIEGO, April 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate

Next

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.